4.2 RSI Induction Agents: Pharmacology, Selection & Dosing

4.2 RSI Induction Agents: Pharmacology, Selection & Dosing

Neuropharmacology of Induction in Rapid Sequence Intubation

Induction in Rapid Sequence Intubation (RSI) requires the rapid intravenous administration of a therapeutic dose of a sedative-hypnotic agent capable of producing immediate loss of consciousness, profound amnesia, and abolition of airway defense reflexes within 15 to 45 seconds. The optimal induction agent must achieve these goals with minimal disruption to systemic hemodynamics, cerebral perfusion pressure, or respiratory mechanics.

Hemodynamic Vulnerability in the Critically Ill

In the emergency department and intensive care unit, up to 10% of patients experience peri-intubation cardiac arrest or profound post-intubation circulatory collapse. Critically ill patients presenting with sepsis, polytrauma, or cardiogenic shock maintain arterial blood pressure and organ perfusion through maximal endogenous sympathetic tone—high circulating levels of epinephrine and norepinephrine coupled with intense systemic vasoconstriction. Administration of an induction agent abruptly eliminates this sympathetic compensatory drive, relaxes vascular tone, and can unmask profound occult hypovolemia. Selecting the appropriate induction agent and tailoring the dose to the patient's underlying physiological reserve is a primary clinical responsibility of the emergency medicine specialist.

---

Agent Pharmacology and Clinical Selection

1. Etomidate: Hemodynamic Stability & Adrenal Endocrinology

• Receptor Target & Mechanism: A carboxylated imidazole derivative that acts as a potent, selective positive allosteric modulator of $\text{GABA}_A$ receptors containing $\beta_2$ or $\beta_3$ subunits. Etomidate enhances the inhibitory effects of gamma-aminobutyric acid by increasing chloride channel opening duration, producing rapid central nervous system depression.
• Dosing & Pharmacokinetics:
  • Standard Induction Dose: 0.3 mg/kg IV (based on actual body weight; 20–30 mg in typical adults).
  • Shock Dose Adjustment: 0.15 to 0.2 mg/kg IV in profound decompensated shock or severe elderly debility.
  • Onset & Duration: Onset within 15 to 30 seconds; duration of action 5 to 10 minutes due to rapid redistribution from the brain into peripheral tissues. Rapidly cleared by hepatic and plasma esterases into inactive metabolites.
• Hemodynamic Profile: Etomidate is remarkably hemodynamically neutral. It does not induce myocardial depression, preserves peripheral vascular resistance, maintains heart rate, and preserves coronary artery perfusion pressure. It is the first-line induction agent of choice in undifferentiated shock, polytrauma with hemorrhage, and severe cardiovascular collapse.
• Central Nervous System Effects: Decreases the cerebral metabolic rate of oxygen ($\text{CMRO}_2$) by approximately 45%, decreases cerebral blood flow (CBF), and reduces intracranial pressure (ICP) while preserving mean arterial pressure, thereby optimizing cerebral perfusion pressure ($\text{CPP} = \text{MAP} - \text{ICP}$).
• The Adrenal Cortical Suppression Controversy:
  • Biochemical Mechanism: Etomidate contains an imidazole ring that binds with high affinity to the heme moiety of cytochrome P450 enzymes within the adrenal cortex. It selectively and reversibly inhibits 11-beta-hydroxylase (CYP11B1), the enzyme responsible for converting 11-deoxycortisol to cortisol and 11-deoxycorticosterone to corticosterone. A single RSI induction dose produces measurable adrenocortical suppression that persists for 12 to 24 hours.
  • Clinical Trial Evidence: Biochemical adrenal suppression is real, and post-hoc analyses (including a CORTICUS substudy) raised concern in sepsis. Randomized data are reassuring:
    • KETASED (Lancet 2009, 655 patients): etomidate versus ketamine for emergency intubation showed no difference in maximum SOFA score or 28-day mortality.
    • RSI trial (Casey et al., NEJM 2025, 2,365 critically ill adults in EDs and ICUs): in-hospital death by day 28 was 28.1% with ketamine vs 29.1% with etomidate (no significant difference), while cardiovascular collapse during intubation was more common with ketamine (22.1% vs 17.0%), especially in sepsis (30.6% vs 20.9%).
    • Single-dose etomidate therefore remains a standard induction agent in septic shock and critical illness.
• Adverse Effects & Cautions: Transient myoclonus (observed in 30% to 60% of unparalyzed patients, caused by subcortical disinhibition and completely eliminated by concurrent NMBA administration), pain on peripheral injection (secondary to the 35% propylene glycol solvent vehicle), and postoperative nausea and vomiting. Etomidate possesses no analgesic properties.

2. Ketamine: Dissociative Anesthesia, Bronchodilation & Shock Paradox

• Receptor Target & Mechanism: A phencyclidine (PCP) derivative that acts as a non-competitive antagonist at the phencyclidine binding site within the N-methyl-D-aspartate (NMDA) receptor-gated calcium ion channel complex. By blocking glutamate transmission, ketamine uncouples the limbic system from the thalamoneocortical cortex, inducing a unique state of dissociative anesthesia (eyes remain open with slow nystagmic gaze, corneal and laryngeal reflexes are preserved, and the patient displays profound amnesia and somatic analgesia).
• Dosing & Pharmacokinetics:
  • Standard Induction Dose: 1 to 2 mg/kg IV (the RSI trial dosed by actual body weight; many references use ideal or lean body weight in obesity; 100–150 mg in typical adults).
  • Shock Dose Adjustment: 0.5 to 1.0 mg/kg IV in profound, unresuscitated shock.
  • Onset & Duration: Onset within 30 to 60 seconds; clinical duration of dissociation is 10 to 20 minutes, with redistribution half-life of 10 to 15 minutes. Metabolized hepatically via CYP3A4/CYP2B6 to norketamine (active metabolite with one-third the potency of ketamine).
• Cardiovascular Dual Pharmacology & The Catecholamine-Depleted State:
  • Normal Physiology: Ketamine stimulates the central sympathetic nervous system and inhibits the neuronal reuptake of catecholamines (norepinephrine and epinephrine). In patients with intact autonomic reserves, this indirect sympathomimetic action elevates systolic and diastolic blood pressure, heart rate, cardiac output, and systemic vascular resistance (SVR).
  • The Catecholamine-Depleted Paradox: Ketamine is an intrinsic direct negative inotrope and myocardial depressant. Under normal conditions, its indirect central sympathomimetic stimulation completely overshadows this direct cardiac depression. However, in critically ill patients with prolonged, end-stage septic or hemorrhagic shock whose endogenous catecholamine stores are fully exhausted, ketamine's direct myocardial depressant effect is unmasked, which can cause precipitous hypotension or cardiac arrest. Dosing must be reduced to 0.5 to 1.0 mg/kg IV in severely depleted states.
• Pulmonary Mechanics: Ketamine is a potent bronchodilator. It relaxes bronchial smooth muscle through catecholamine-mediated $\beta_2$-adrenergic stimulation and direct vagolytic antagonism of muscarinic receptors. It preserves functional residual capacity and spontaneous respiratory drive. Ketamine is the unquestioned induction agent of choice in acute status asthmaticus and severe reactive bronchospasm.
• Intracranial Pressure (Debunking the Dogma): Historical dogma claimed ketamine increased ICP and was strictly contraindicated in traumatic brain injury (TBI). Modern neurocritical care trials (Zeiler et al., 2014; Ballow et al., 2014) demonstrate that when mechanical ventilation is controlled and normocapnia is maintained (avoiding hypoventilation-induced hypercapnic cerebral vasodilation), ketamine does not increase ICP. By supporting systemic blood pressure, ketamine maintains cerebral perfusion pressure, making it safe and effective in neurotrauma.
• Emergence Phenomena: Vivid dreams, hallucinations, and psychotomimetic agitation occur in 10% to 20% of adult patients upon awakening. These are effectively mitigated by post-intubation co-administration of low-dose benzodiazepines or propofol.

3. Propofol: Neuroprotection, Rapid Clearance & Vasodilatory Hypotension

• Receptor Target & Mechanism: An alkylphenol derivative (2,6-diisopropylphenol) formulated in a 10% oil-in-water lipid emulsion (soybean oil, glycerol, and egg lecithin). It binds to $\beta$-subunits of the $\text{GABA}_A$ receptor, directly activating and allosterically enhancing inhibitory chloride channel conductance. It also inhibits NMDA receptors and modulates cannabinoid receptor systems.
• Dosing & Pharmacokinetics:
  • Standard Induction Dose: 1.5 to 2.5 mg/kg IV (based on ideal body weight; 100–150 mg in typical adults).
  • Shock / Hemodynamically Fragile Dose: 0.5 to 1.0 mg/kg IV (or avoided entirely in shock states).
  • Onset & Duration: Ultra-rapid onset of 15 to 30 seconds; ultra-short clinical duration of 5 to 8 minutes secondary to rapid redistribution. Rapidly metabolized hepatically by glucuronidation and sulfation.
• Cardiovascular Toxicity: Propofol is the most hemodynamically destabilizing induction agent. It induces marked arterial and venous vasodilation by reducing sympathetic vasoconstrictor tone and directly relaxing vascular smooth muscle. Furthermore, it exerts direct dose-dependent negative inotropic effects on the myocardium and impairs baroreceptor reflex responses. Mean arterial pressure typically falls by 20% to 40% following bolus administration. It is contraindicated as an induction monotherapy in hypovolemia, trauma, or septic shock.
• Neuroprotective Properties: Propofol markedly reduces $\text{CMRO}_2$ (by up to 36%), decreases CBF, and causes profound reductions in ICP. It possesses potent anticonvulsant properties, terminating status epilepticus by suppressing epileptogenic electrical foci. It is the agent of choice for RSI in refractory status epilepticus and severe traumatic brain injury with preserved systemic hemodynamics.
• Allergy Nuances: Egg allergy is not an absolute contraindication unless the patient has a documented history of severe anaphylaxis to egg yolk lecithin (most egg allergies involve egg white ovalbumin). Formulated at 1.1 kcal/mL in lipid emulsion, which must be tracked during continuous ICU infusions.

4. Midazolam: The 'Sedative vs. Induction' Dosing Fallacy

• Receptor Target & Mechanism: A water-soluble imidazobenzodiazepine that crosses the blood-brain barrier rapidly and acts as a positive allosteric modulator of $\text{GABA}_A$ receptors, increasing chloride ion influx frequency.
• Dosing & Pharmacokinetics:
  • True RSI Induction Dose: 0.2 to 0.3 mg/kg IV (15 to 25 mg in a typical 70-kg adult).
  • Onset & Duration: Unacceptably slow onset of 90 to 180 seconds (even longer in elderly or low-cardiac-output patients); prolonged clinical duration of 15 to 30 minutes (up to hours in renal/hepatic failure due to accumulation of active 1-hydroxymidazolam glucuronide).
• The Critical Clinical Pitfall (Sedation vs. Induction): Emergency clinicians frequently order 2 to 5 mg IV of midazolam (0.03 to 0.05 mg/kg) under the mistaken belief that it serves as an RSI induction agent. A 2 to 5 mg dose provides light conscious sedation and anxiolysis; it does not induce general anesthesia, loss of consciousness, or suppression of airway reflexes. Paralyzing a patient who has received only 2 to 5 mg of midazolam results in catastrophic awareness during paralysis, inflicting extreme psychological terror and triggering massive autonomic hypertension and tachycardia. Furthermore, when midazolam is pushed at true induction doses (0.2–0.3 mg/kg), its onset is unacceptably delayed (2–3 minutes) and it produces severe peripheral vasodilation and myocardial depression comparable to propofol. Midazolam is considered a distinctly inferior primary induction agent for emergency RSI.

---

RSI Induction Agent Comparison Matrix

---

Worked Clinical Case & Practice Pearls

Clinical Vignette

A 42-year-old female (actual weight 65 kg, height 5'5") with a history of severe brittle asthma is brought by EMS to the emergency department in near-fatal status asthmaticus. She is sitting in a tripod position, using accessory muscles of respiration, and unable to speak more than single syllables. Vital signs: blood pressure 152/92 mmHg, heart rate 134 bpm, respiratory rate 38 breaths/min, and $SpO_2$ 88% on a non-rebreather mask. Bilateral breath sounds reveal marked expiratory wheezing with areas of 'silent chest' at the lung bases. Arterial blood gas demonstrates acute respiratory muscle fatigue and carbon dioxide narcosis: pH 7.14, $\text{PaCO}_2$ 74 mmHg, $\text{PaO}_2$ 58 mmHg, and $\text{HCO}_3^-$ 24 mEq/L. Despite continuous nebulized albuterol, ipratropium, IV magnesium sulfate (2 g), and IV methylprednisolone (125 mg), she becomes increasingly somnolent. The emergency team initiates RSI.

Pharmacotherapeutic Care Plan

1. Preoxygenation: Apply 100% $FiO_2$ via NIPPV with low PEEP (5 $\text{cmH}_2\text{O}$) and high pressure support to overcome intrinsic PEEP and maximize denitrogenation.
2. Induction Agent Selection: Ketamine 2.0 mg/kg IV $\times$ 65 kg = 130 mg IV push.
   • Pharmacological Rationale: Ketamine directly relaxes bronchial smooth muscle through $\beta_2$-adrenoceptor stimulation via endogenous catecholamine release and direct vagolytic muscarinic antagonism. It maintains hemodynamic stability and provides immediate dissociative unconsciousness without worsening respiratory acidosis.
3. Neuromuscular Blocker Selection: Rocuronium 1.2 mg/kg IV $\times$ 65 kg = 78 mg IV (rounded to 80 mg).
   • Rationale: Provides complete motor paralysis within 60 seconds without triggering histamine release (which can exacerbate bronchospasm).
4. Outcome: The patient is successfully intubated on the first attempt with a 7.5-mm ETT. Mechanical ventilation is initiated with an obstructive lung strategy (low tidal volume 6 mL/kg, low respiratory rate 10–12 breaths/min, and long expiratory time to prevent dynamic hyperinflation and auto-PEEP). Post-intubation ketamine continuous infusion (1 mg/kg/h) and propofol infusion (20 mcg/kg/min) are started immediately.